Abstract
Objective: To compare the effectiveness of Nebivolol and Bisoprolol in reducing hospitalizations and mortality in heart failure patients at Tertiary care hospital, Peshawar, between June 2022 and June 2023.
Methodology: A retrospective study was conducted with 400 heart failure patients, equally divided into two groups (Nebivolol and Bisoprolol). Demographic data, hospitalizations, length of stay, mortality rates, and comorbidities were extracted from patient records. Statistical analysis included independent t-tests for continuous variables and chi-square tests for categorical variables, with significance set at p < 0.05.
Results: The Nebivolol group had 120 hospitalizations (60%), and the Bisoprolol group had 130 hospitalizations (65%) (p = 0.24). The average length of stay for Nebivolol was 8.5 days (SD = 2.3) and for Bisoprolol was 9.1 days (SD = 2.7) (p = 0.12). Mortality rates were significantly lower in the Nebivolol group, with 20 deaths (10%) compared to 30 deaths (15%) in the Bisoprolol group (p = 0.03). Hypertension and ischemic heart disease were the most common comorbidities, and both were significantly linked to increased mortality.
Conclusion: The study suggests that Nebivolol is associated with a lower mortality rate compared to Bisoprolol in heart failure patients, although both drugs show similar effects on hospitalization rates and length of stay. These findings support further research with larger, multicenter studies to validate the benefits of Nebivolol in diverse populations.